Main > ONCOLOGY (**) > Lung>NSCLC>Resectable (tumors>4cm o > NeoAdjuvant TREAT.: > USA. B. PD-1 MAb+Pt Doublet CT>

---

USA. B. PD-1 MAb+Pt Doublet CT>'s subsections
(*) USA Approval Date: 2022. 03.04
>Every 3 Weeks for 3 Cycles
Company
Generic Name: NivoluMAb
Patent>Assignee; Claims; No.; Etc.
PR Web-Site
RTM
RTM Web-Site

USA. B. PD-1 MAb+Pt Doublet CT>'s products
This section has no products